AR057959A1 - 5-pirazolpiperidinas-(sustituidas) - Google Patents
5-pirazolpiperidinas-(sustituidas)Info
- Publication number
- AR057959A1 AR057959A1 ARP060105326A ARP060105326A AR057959A1 AR 057959 A1 AR057959 A1 AR 057959A1 AR P060105326 A ARP060105326 A AR P060105326A AR P060105326 A ARP060105326 A AR P060105326A AR 057959 A1 AR057959 A1 AR 057959A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- optionally substituted
- aryl
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Los compuestos de la formula (1) son utiles al tratar o prevenir trastornos cognitivos, tales como la Enfermedad de Alzheimer. La presente también abarca composiciones farmacéuticas que comprenden compuestos de la formula (1) así como métodos para tratar desordenes cognitivos, tales como la Enfermedad de Alzheimer. Reivindicacion 1: Los compuestos de la formula (1) esteroisomeros, tautomeros, mezclas de esteroisomeros y/o tautomeros o sales farmacéuticamente aceptables de la misma, en donde el anillo A es arilo, cicloalquilo, heteroarilo o heterocicloalquilo, donde cada anillo está sustituido opcionalmente en una posicion sustituible con halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, haloalquilo C1-6, haloalcoxi C1-6, hidroxilo, hidroxialquilo, CN, ariloxi, arilalquiloxi, -SO2-(alquilo C1-6), -NR'Rö, alcoxi C1-6, alquilo C0-3-C(O)OR', heteroarilo, heterocicloalquilo, arilo, arilalquilo, o -SO2-NR'Rö, donde cada R' y Rö es independientemente H o alquilo C1-6 o R' y Rö con el átomo al cual están unidas pueden formar un anillo de 3-8 miembros que opcionalmente incluyen un heteroátomo adicional tal como N, O o S; el anillo B es un anillo heteroarilo o heterocicloalquilo, cada uno de los cuales está sustituido opcionalmente en una posicion sustituible con un grupo que es independientemente alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, amino, alquiloamino C1-6, dialquiloamino C1-6, -S(O)0-2R', hidroxilo, hidroxialquilo, halo, haloalquilo C1-2, haloalcoxi C1-2, -NR'C(O)Rö, -NR'SO2Rö, -C(O)R', -CO2R', alquilo-C(O)OC(O)R', -C(O)NR'Rö, oxo, CN, o alquilarilo C0-1, donde el arilo se sustituye opcionalmente con 1-5 grupos independientemente seleccionados de halogeno, alquilo C1-6, -C(O)OR'alcoxi, haloalquilo C1-6, haloalcoxi, hidroxilo, CN, NO2,ariloxi, -S(O)0-2-(alquilo C1-6), -C(O)NR'Rö, -NR'Rö, alcanoilo C1-6, piridilo, fenilo, y -SO2NR'Rö; y R1, R1a, R2 y R2a, son independientemente H, halogeno, alquilo C1-6, alquenilo C2-6 donde el grupo alquenilo es sustituido opcionalmente con uno o más halogenos; alquinilo C2-6, cicloalquilo C3-6, cicloalquilo C3-6-alquilo C1-6, arilo, arilalquilo C1-6, heteroarilo, -CO2R', CONR'Rö, haloalquilo C1-6, donde el grupo haloalquilo se sustituye opcionalmente con alcoxi C1-4, haloalcoxialquilo C1-4, hidroxi alquilo C1-6, alcanoilo C2-6, ariloxi alquilo C1-6, heteroariloxi alquilo C1-6, alquilo C0-6, OC(O)NR'Rö, o alquilo C0-6, -OC(O)-heterocicloalquilo C0-6, en donde cada arilo, heteroarilo y grupo heterocicloalquilo se sustituye opcionalmente con uno o más grupos que son independientemente halogeno, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, halo alquilo C1-4, halo alcoxi C1-4, -C(O)NR'Rö, -NR'Rö, hidroxilo, -O-(CH2)1-2-O-, -C(O)OR', fenilo, piridazinilo, pirazinilo, pirimidinilo, tiazolilo, piridilo, N-metil pirazolilo, N-bencil pirazolilo, oxadiazolilo, oxazolilo o imidazolilo; R3 y R3a son independientemente H, halogeno o alquilo C1-6; R1 y R1a, o R2 y R2a o R3 y R3a se combinan para formar =O o =N-OR, donde R es H, alquilo C1-6, arilo (tal como fenilo) o arilalquilo (tal como bencilo o fenetilo); o R1, y R1a, o R2 y R2a o R3 y R3a juntos con el C al cual están unidos forman el grupo cicloalquilo C3-6 en donde uno de los carbonos es reemplazado opcionalmente con un heteroátomo seleccionado de N, O o S y en donde dicho anillo puede ser opcionalmente sustituido con alquilo C1-6, o R1 y R3 forman un enlace. doble.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74136605P | 2005-12-01 | 2005-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057959A1 true AR057959A1 (es) | 2007-12-26 |
Family
ID=38092841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105326A AR057959A1 (es) | 2005-12-01 | 2006-12-01 | 5-pirazolpiperidinas-(sustituidas) |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7732609B2 (es) |
| EP (1) | EP1957458A2 (es) |
| JP (1) | JP2009518301A (es) |
| KR (1) | KR20080073359A (es) |
| CN (1) | CN101370776A (es) |
| AR (1) | AR057959A1 (es) |
| AU (1) | AU2006320423B2 (es) |
| BR (1) | BRPI0619633A2 (es) |
| CA (1) | CA2632227A1 (es) |
| EA (1) | EA014906B1 (es) |
| EC (1) | ECSP088593A (es) |
| IL (1) | IL190608A0 (es) |
| MA (1) | MA30089B1 (es) |
| MY (1) | MY149422A (es) |
| NZ (1) | NZ568109A (es) |
| PE (1) | PE20071090A1 (es) |
| TW (1) | TW200736255A (es) |
| WO (1) | WO2007064914A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007006010D1 (de) * | 2006-05-31 | 2010-06-02 | Galapagos Nv | Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| JP2010528036A (ja) * | 2007-05-25 | 2010-08-19 | エラン ファーマシューティカルズ，インコーポレイテッド | γセクレターゼの阻害剤としてのピラゾロピロリジン |
| ES2397764T3 (es) | 2008-04-01 | 2013-03-11 | Abbott Gmbh & Co. Kg | Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| CN102439010A (zh) * | 2009-03-25 | 2012-05-02 | 艾伦药物公司 | 稠合三环磺酰胺的制备方法 |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| MX2014001457A (es) | 2011-08-05 | 2014-08-21 | Abbvie Deutschland | Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia. |
| WO2013072520A1 (en) | 2011-11-18 | 2013-05-23 | AbbVie Deutschland GmbH & Co. KG | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| AU2014336154A1 (en) | 2013-10-17 | 2016-04-28 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| SG11201602982YA (en) | 2013-10-17 | 2016-05-30 | Abbvie Deutschland | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN104059063A (zh) * | 2014-04-03 | 2014-09-24 | 丽水绿氟科技有限公司 | 7,7-二氟-4,5,6,7-四氢吡唑并[4,3-c]吡啶及其衍生物的制备方法 |
| ES2910071T3 (es) | 2018-03-08 | 2022-05-11 | Incyte Corp | Compuestos de aminopirazina diol como inhibidores de PI3K-Y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09511758A (ja) * | 1994-10-20 | 1997-11-25 | フアイザー・インコーポレイテツド | 二環式テトラヒドロピラゾロピリジンおよび医薬としてのその使用 |
| CA2416527C (en) * | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| ES2319879T3 (es) * | 2001-10-09 | 2009-05-14 | Kyorin Pharmaceutical Co., Ltd. | 4-(2-furoil)aminopiperidinas novedosas, productos intermedios en la sintesis de las mismas, procedimiento para producir las mismas y uso medico de las mismas. |
| AU2003292724A1 (en) * | 2002-12-27 | 2004-07-29 | Japan Tobacco Inc. | Fused n-containing heterocyclic compounds and medicinal use thereof |
| WO2005113542A2 (en) * | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| US20060089378A1 (en) | 2004-10-27 | 2006-04-27 | Mingde Xia | Tetrahydro-pyridinyl pyrazole cannabinoid modulators |
| DE102005002500A1 (de) * | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
| WO2006101434A1 (en) * | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| DE102005016170A1 (de) * | 2005-04-07 | 2006-10-12 | Grünenthal GmbH | 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| KR20080042135A (ko) * | 2005-08-19 | 2008-05-14 | 엘란 파마슈티칼스, 인크. | 감마 세크레타제 억제제로서의 브릿징된 ｎ비사이클릭설폰아미도 |
-
2006
- 2006-12-01 EP EP06844721A patent/EP1957458A2/en not_active Withdrawn
- 2006-12-01 JP JP2008543496A patent/JP2009518301A/ja active Pending
- 2006-12-01 AU AU2006320423A patent/AU2006320423B2/en not_active Ceased
- 2006-12-01 MY MYPI20081060A patent/MY149422A/en unknown
- 2006-12-01 CN CNA2006800451866A patent/CN101370776A/zh active Pending
- 2006-12-01 PE PE2006001542A patent/PE20071090A1/es not_active Application Discontinuation
- 2006-12-01 WO PCT/US2006/046039 patent/WO2007064914A2/en active Application Filing
- 2006-12-01 EA EA200801481A patent/EA014906B1/ru not_active IP Right Cessation
- 2006-12-01 US US11/566,070 patent/US7732609B2/en not_active Expired - Fee Related
- 2006-12-01 AR ARP060105326A patent/AR057959A1/es not_active Application Discontinuation
- 2006-12-01 BR BRPI0619633-0A patent/BRPI0619633A2/pt not_active Application Discontinuation
- 2006-12-01 NZ NZ568109A patent/NZ568109A/en not_active IP Right Cessation
- 2006-12-01 CA CA002632227A patent/CA2632227A1/en not_active Abandoned
- 2006-12-01 TW TW095144766A patent/TW200736255A/zh unknown
- 2006-12-01 KR KR1020087015935A patent/KR20080073359A/ko not_active Application Discontinuation
-
2008
- 2008-04-03 IL IL190608A patent/IL190608A0/en unknown
- 2008-06-26 MA MA31080A patent/MA30089B1/fr unknown
- 2008-07-01 EC EC2008008593A patent/ECSP088593A/es unknown
-
2010
- 2010-06-08 US US12/796,441 patent/US20100267747A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2632227A1 (en) | 2007-06-07 |
| MA30089B1 (fr) | 2008-12-01 |
| CN101370776A (zh) | 2009-02-18 |
| BRPI0619633A2 (pt) | 2011-10-04 |
| ECSP088593A (es) | 2008-08-29 |
| MY149422A (en) | 2013-08-30 |
| EA014906B1 (ru) | 2011-02-28 |
| IL190608A0 (en) | 2008-11-03 |
| WO2007064914A3 (en) | 2007-12-27 |
| JP2009518301A (ja) | 2009-05-07 |
| US20070155753A1 (en) | 2007-07-05 |
| EP1957458A2 (en) | 2008-08-20 |
| KR20080073359A (ko) | 2008-08-08 |
| AU2006320423B2 (en) | 2012-06-21 |
| WO2007064914A8 (en) | 2008-05-15 |
| US7732609B2 (en) | 2010-06-08 |
| US20100267747A1 (en) | 2010-10-21 |
| WO2007064914A2 (en) | 2007-06-07 |
| PE20071090A1 (es) | 2007-10-24 |
| NZ568109A (en) | 2011-07-29 |
| AU2006320423A1 (en) | 2007-06-07 |
| EA200801481A1 (ru) | 2009-02-27 |
| TW200736255A (en) | 2007-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057959A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| CY1121231T1 (el) | Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης | |
| AR075050A1 (es) | Dicianopiridinas alquilamino-sustituidas | |
| AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| AU2015341913A1 (en) | Pharmaceutical compound | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR056470A1 (es) | Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa | |
| AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
| PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR043051A1 (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| AR038823A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR035716A1 (es) | Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos | |
| PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
| AR067845A1 (es) | Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR050536A1 (es) | Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprenden | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR054208A1 (es) | Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios | |
| AR076235A1 (es) | Compuestos organicos y sus usos | |
| AR045113A1 (es) | Derivados sustituidos del dioxido de tiazolbenzoisotiazol, procedimiento para su preparacion y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |